The Missouri medical cannabis market was valued at USD 394.1 million in 2022 and is projected to grow significantly at a compound annual growth rate (CAGR) of 21.40% from 2023 to 2030. The foundation for this rapid growth was laid in November 2018, when Missouri officially legalized medical cannabis, creating a framework for regulated use and distribution throughout the state.

Several factors are contributing to the strong expansion of this market. Key among them is the increasing body of research highlighting the health benefits of cannabis-based products, which has begun to reshape public and medical community perceptions. As scientific studies continue to support the therapeutic potential of cannabis, more patients and healthcare providers are embracing it as a viable treatment option for a range of conditions. Alongside research, growing public awareness and education efforts have also played a critical role in helping patients understand the medical advantages of cannabis.

In Missouri specifically, the rising prevalence of chronic conditions—such as epilepsy, glaucoma, PTSD, bipolar disorder, schizophrenia, and cancer-related symptoms—has led to increased demand for alternative treatment options. Medical cannabis has gained recognition for its potential to alleviate symptoms such as pain, nausea, appetite loss, and anxiety, particularly among patients undergoing chemotherapy or dealing with long-term illnesses.

The legalization of medical cannabis in the state has also opened up substantial business opportunities, paving the way for the emergence and expansion of local and national players. One notable example is BeLeaf Medical, based in St. Louis, which became Missouri’s first licensed medical cannabis cultivator in June 2020. As a vertically integrated company, BeLeaf holds ten licenses in the state, covering various aspects of production and distribution. Such strategic moves are enabling companies to establish a firm foothold in the growing market.

Furthermore, the continued inclusion of additional health conditions under Missouri’s medical marijuana program has played a key role in driving patient adoption. For instance, by December 2019, the Department of Health and Senior Services (DHSS) had received 2,200 pre-filled application forms, and over 22,000 Missourians had successfully obtained qualified patient ID cards, granting them access to medical cannabis products. These figures demonstrate both the demand and readiness of the population to adopt medical cannabis, signaling promising opportunities for future market growth.

However, it's important to note that recreational use of cannabis is still not legalized in Missouri, which may act as a limiting factor in the market’s full expansion. Nonetheless, the widening scope of medical conditions approved for cannabis treatment, combined with a robust patient base and evolving public attitudes, is expected to continue fueling strong growth in the Missouri medical cannabis industry throughout the forecast period.

Key Market Trends & Insights:

• In 2022, the chronic pain segment accounted for the largest share of revenue, representing over 25.7% of the total medical cannabis market in Missouri. This strong performance can be attributed to multiple contributing factors. Chief among them is the growing body of scientific research supporting the effectiveness of cannabis in managing and alleviating chronic pain. Numerous studies have demonstrated that cannabinoids can help reduce inflammation, modulate pain signals, and provide relief in cases where conventional treatments may fall short. Additionally, the high prevalence of chronic pain among Missouri's population has created a substantial patient base, further driving demand for cannabis-based therapeutic solutions.

• Meanwhile, the oils and tinctures segment emerged as the market leader in 2022, securing a revenue share of over 53.7%. These products have become increasingly popular due to their ease of administration, precise dosage control, and discreet consumption methods, which make them appealing to a wide range of medical cannabis users. Furthermore, this segment is projected to be the fastest-growing over the forecast period. This anticipated growth is primarily fueled by rising demand among patients seeking relief from conditions such as epilepsy, PTSD, autism, chronic pain, and muscle spasms related to multiple sclerosis or Parkinson’s disease, as well as convulsions.

Order a free sample PDF of the Missouri Medical Cannabis Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 394.1 million

• 2030 Projected Market Size: USD 2.0 billion

• CAGR (2022-2030): 21.40% 

Key Companies & Market Share Insights:

Cannabis products offer a wide range of medical benefits to consumers, which has significantly contributed to their increasing adoption for the treatment of various chronic illnesses. These benefits include pain relief, reduction of inflammation, management of neurological disorders, and improvement of mental health conditions, among others. As awareness of these therapeutic advantages continues to grow, cannabis products are rapidly gaining popularity and acceptance within both the medical community and among patients. This growing acceptance has fueled a surge in their usage, making cannabis an increasingly preferred option for managing chronic health conditions.

In response to this expanding market, key players in the industry are actively pursuing strategic initiatives aimed at strengthening their presence and increasing their market shares. These initiatives include forming partnerships, executing mergers and acquisitions, collaborating with other influential market participants, and launching innovative products tailored to meet diverse patient needs. Such strategies not only enhance product portfolios but also help companies expand their distribution networks and improve market penetration.

For example, in January 2022, Organic Remedies Missouri announced the launch of its specialized product line designed specifically for medical marijuana patients within the state. This move exemplifies how market participants are focusing on localized product development and catering to specific patient demographics, thereby gaining a competitive edge.

Key Players

• BeLeaf Medical

• Blue Sage Cannabis Co.

• Show Me Alternatives

• Heya Wellness

• Missouri Wild Alchemy

• Organic Remedies

• Holistic Industries

• Kansas City Cannabis

• LOCAL CANNABIS COMPANY

• MOcann Extracts

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The Missouri medical cannabis market is poised for significant growth driven by increasing patient awareness, expanding qualifying medical conditions, and ongoing research supporting the therapeutic benefits of cannabis. Legalization has created substantial opportunities for businesses, attracting both local and national players. However, the absence of recreational cannabis legalization may limit the market’s full potential. Continued strategic developments, along with rising demand for diverse cannabis products, are expected to sustain market momentum over the coming years.